APO-Bortezomib bortezomib 3.5mg powder for injection vial

国家: 澳大利亚

语言: 英文

来源: Department of Health (Therapeutic Goods Administration)

有效成分:

bortezomib, Quantity: 3.5 mg

可用日期:

Arrotex Pharmaceuticals Pty Ltd

INN（国际名称）:

Bortezomib

药物剂型:

Injection, powder for

组成:

Excipient Ingredients: mannitol

给药途径:

Subcutaneous, Intravenous

每包单位数:

1

处方类型:

(S4) Prescription Only Medicine

疗效迹象:

Bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,Bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy and who have progressive disease.

產品總結:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

授权状态:

Licence status A

授权日期:

2015-07-22